Novo Nordisk Shares Plunge on Insulin's FDA Failure

Feb. 11 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk shares have fallen the most in a decade as the company's new insulin drug Tresiba has failed to win FDA approval in the United States. She speaks on Bloomberg Television's "The Pulse."
Bullard: Recent Volatility Won't Alter Fed's Outlook
52:00 - Federal Reserve Bank of St. Louis President James Bullard talks about the outlook for monetary policy, the U.S. economy and recent market volatility. He speaks from Jackson Hole, Wyoming, with Brendan Greeley, Michael McKee and Tom Keene on Bloomberg Television's "Surveillance." (Source: Bloomberg)
  • Inflation Takes Center Stage in Fed's Rate Debate
  • BoE Likely to Raise Rates in February: HSBC's Martins
  • El-Erian: Fed Has Goldilocks Problem With Volatility